临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2014年
11期
1966-1968
,共3页
谢伟国%江莲%谢诤%张洁
謝偉國%江蓮%謝諍%張潔
사위국%강련%사쟁%장길
信必可都保%支气管哮喘%孟鲁斯特
信必可都保%支氣管哮喘%孟魯斯特
신필가도보%지기관효천%맹로사특
symbicort turbuhaler%bronchial asthma%montelukast
目的:比较孟鲁斯特(顺尔宁)联合信必可都保与单用信必可都保治疗支气管哮喘的疗效差异。方法将60例支气管哮喘患者随机分两组,分别为单用信必可都保组和顺尔宁联合信必可都保组,治疗为期一年。比较治疗前后临床症状及肺功能的改变,在治疗结束后,随访1年。对其复发率进行评估。结果两组治疗前后临床症状及肺功能均有明显改善;顺尔宁联合信必可都保临床症状及肺功能改善更迅速,疗效更显著(P<0.05);1年随访,联合应用组复发率更低;两组间比较有统计学意义。结论顺尔宁联合信必可都保能更迅速,更有效的改善支气管哮喘的临床症状和肺功能,且复发率低。
目的:比較孟魯斯特(順爾寧)聯閤信必可都保與單用信必可都保治療支氣管哮喘的療效差異。方法將60例支氣管哮喘患者隨機分兩組,分彆為單用信必可都保組和順爾寧聯閤信必可都保組,治療為期一年。比較治療前後臨床癥狀及肺功能的改變,在治療結束後,隨訪1年。對其複髮率進行評估。結果兩組治療前後臨床癥狀及肺功能均有明顯改善;順爾寧聯閤信必可都保臨床癥狀及肺功能改善更迅速,療效更顯著(P<0.05);1年隨訪,聯閤應用組複髮率更低;兩組間比較有統計學意義。結論順爾寧聯閤信必可都保能更迅速,更有效的改善支氣管哮喘的臨床癥狀和肺功能,且複髮率低。
목적:비교맹로사특(순이저)연합신필가도보여단용신필가도보치료지기관효천적료효차이。방법장60례지기관효천환자수궤분량조,분별위단용신필가도보조화순이저연합신필가도보조,치료위기일년。비교치료전후림상증상급폐공능적개변,재치료결속후,수방1년。대기복발솔진행평고。결과량조치료전후림상증상급폐공능균유명현개선;순이저연합신필가도보림상증상급폐공능개선경신속,료효경현저(P<0.05);1년수방,연합응용조복발솔경저;량조간비교유통계학의의。결론순이저연합신필가도보능경신속,경유효적개선지기관효천적림상증상화폐공능,차복발솔저。
Objective To compare the efficiency of montelukast plus symbicort turbuhaler and symbicort tur-buhaler only in the treatment of patients with bronchial asthma. Methods 60 patients with bronchial asthma were randomly divided into two groups. The treatment group was treated with Montelukast plus symbicort turbuhaler, and the control group was given symbicort turbuhaler only for one year. The pulmonary function and clinical symptoms be-fore and after treatment were observed in the two groups, and the recurrence rate was observed strictly for 2 years. Results Before and after the treatment, their clinical symptoms and pulmonary function of the two groups were all improved, but the improvement was more pronounced in the treatment group than in the control group (P<0. 05). The recurrence rate was lower in the treatment group than in the control group. Conclusion Montelukast plus symbi-cort turbuhaler can effectively improve their clinical symptoms and pulmonary function in the treatment of patients with bronchial asthma.